source
- NeuShen Therapeutics raises over $80 million to advance three brain-health drug candidatesNeuShen Therapeutics, a biotech with operations in Shanghai and Boston, announced it has closed a Series B financing round of more than $80 million. The capital will be used to move three clinical…
- Truist sees biotech rebound as M&A hits $136B and XBI climbs 34% in H1Truist Securities says the biotech sector is regaining momentum after a prolonged post‑pandemic slowdown, driven by rising merger activity, returning venture capital and easing policy risks. The S…